Tags

Type your tag names separated by a space and hit enter

Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.
Biochem Biophys Res Commun. 2006 Jun 02; 344(2):667-74.BB

Abstract

The SR-related-CTD-associated-factors (SCAFs) have the ability to interact with the C-terminal domain of the RNA polymerase II, linking this way transcription to splicing. SRA1 (SR-A1) gene, encoding for a human high-molecular weight SCAF protein, is located on chromosome 19, between the IRF3 and the R-RAS oncogene and it has been demonstrated from members of our group that SRA1 is constitutively expressed in most of the human tissues, while it is overexpressed in a subset of ovarian tumors. In this study, we examine the expression of SRA1 gene in 111 ovarian malignant tissues and in the human ovarian carcinoma cell lines OVCAR-3, TOV21-G, and ES-2, using a semi-quantitative RT-PCR method. SRA1 gene was overexpressed in 61/111 (55%) of ovarian carcinomas. This higher expression was positively associated to the size of the tumor (p<0.001), the grade and the stage of the disease (p=0.003 and p=0.006, respectively), and the debulking success (p<0.001). Kaplan-Meier survival analysis revealed that lower SRA1 expression increases the probability of both the longer overall and the progression free survival of the patients. Multivariate Cox regression analysis revealed that SRA1 may be used as an independent prognostic biomarker in ovarian cancer. Our results suggest that SRA1 is associated with cancer progression and may possibly be characterized as a new marker of unfavorable prognosis for ovarian cancer.

Authors+Show Affiliations

Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, 15711 Panepistimioupoli, Athens, Greece.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16631123

Citation

Leoutsakou, Theoni, et al. "Expression Analysis and Prognostic Significance of the SRA1 Gene, in Ovarian Cancer." Biochemical and Biophysical Research Communications, vol. 344, no. 2, 2006, pp. 667-74.
Leoutsakou T, Talieri M, Scorilas A. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochem Biophys Res Commun. 2006;344(2):667-74.
Leoutsakou, T., Talieri, M., & Scorilas, A. (2006). Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochemical and Biophysical Research Communications, 344(2), 667-74.
Leoutsakou T, Talieri M, Scorilas A. Expression Analysis and Prognostic Significance of the SRA1 Gene, in Ovarian Cancer. Biochem Biophys Res Commun. 2006 Jun 2;344(2):667-74. PubMed PMID: 16631123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. AU - Leoutsakou,Theoni, AU - Talieri,Maroulio, AU - Scorilas,Andreas, Y1 - 2006/04/07/ PY - 2006/03/24/received PY - 2006/03/25/accepted PY - 2006/4/25/pubmed PY - 2006/6/23/medline PY - 2006/4/25/entrez SP - 667 EP - 74 JF - Biochemical and biophysical research communications JO - Biochem Biophys Res Commun VL - 344 IS - 2 N2 - The SR-related-CTD-associated-factors (SCAFs) have the ability to interact with the C-terminal domain of the RNA polymerase II, linking this way transcription to splicing. SRA1 (SR-A1) gene, encoding for a human high-molecular weight SCAF protein, is located on chromosome 19, between the IRF3 and the R-RAS oncogene and it has been demonstrated from members of our group that SRA1 is constitutively expressed in most of the human tissues, while it is overexpressed in a subset of ovarian tumors. In this study, we examine the expression of SRA1 gene in 111 ovarian malignant tissues and in the human ovarian carcinoma cell lines OVCAR-3, TOV21-G, and ES-2, using a semi-quantitative RT-PCR method. SRA1 gene was overexpressed in 61/111 (55%) of ovarian carcinomas. This higher expression was positively associated to the size of the tumor (p<0.001), the grade and the stage of the disease (p=0.003 and p=0.006, respectively), and the debulking success (p<0.001). Kaplan-Meier survival analysis revealed that lower SRA1 expression increases the probability of both the longer overall and the progression free survival of the patients. Multivariate Cox regression analysis revealed that SRA1 may be used as an independent prognostic biomarker in ovarian cancer. Our results suggest that SRA1 is associated with cancer progression and may possibly be characterized as a new marker of unfavorable prognosis for ovarian cancer. SN - 0006-291X UR - https://www.unboundmedicine.com/medline/citation/16631123/Expression_analysis_and_prognostic_significance_of_the_SRA1_gene_in_ovarian_cancer_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(06)00746-7 DB - PRIME DP - Unbound Medicine ER -